Pfizer Inc.
COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER

Abstract:

The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises an anti-PD-L antibody and a DNA-PK inhibitor, optionally together with one or more additional chemotherapeutic agents or radiotherapy. The therapeutic combination is particularly intended for use in treating a subject having a cancer that tests positive for PD-L1 expression.